← All tickers

Is CNTX Worth Buying in 2026?

Context Therapeutics Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-07-26

Here’s whether Context Therapeutics Inc. Common Stock (CNTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Positives: RSI 47 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-21.12% over 10 days); weak 1-year return of -27.0%; 3-month momentum negative (-72.8%). Currently 83.0% off its 52-week high. Score: -5/7.

Ready to act on this? 📈 Trade on Webull

CNTX is trading below its 200-day MA ($1.75) — a key warning sign the longer-term trend is under pressure. An RSI of 46.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -27.0% compares to +16.5% for SPY (trailed the market by 43.4%). The current 83.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $7,304 today
vs. S&P 500 (SPY) — same period trailed market by 43.4%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($1.75)
✗Above 50-day MA ($1.31)
✓RSI(14) neutral zone (30–70) — currently 46.9
✗Positive return (-27.0%)
!Within 10% of period high (−83.0%)
Period Range $0.61
$0.55 $3.62
RSI (14) 46.9
0 · OversoldOverbought · 100

Key Metrics

Price$0.61
Period Return-27.0%
Period High$3.62
Period Low$0.55
Drawdown−83.0%
MA-50$1.31
MA-200$1.75
RSI (14)46.9
Avg Volume (30d)4.0M
vs. SPYtrailed by 43.4%
Return Rank#740 of 999

Trade CNTX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers